Quarterly ResultAug 13, 2026, 07:09 AM
Hepion Pharmaceuticals Reports Q2 Net Loss $1.25M; Going Concern Doubt
AI Summary
Hepion Pharmaceuticals reported a net loss of $1.25 million for the second quarter of 2026 and $2.06 million for the six months ended June 30, 2026. The company's cash balance decreased to $1.63 million, and it issued a going concern warning due to recurring losses and negative cash flows. To address funding needs, Hepion completed a $0.7 million private placement in April 2026 and a $3.1 million offering in July 2026. The company also entered into a license agreement for liver disease diagnostic assets and signed new employment agreements with its Executive Chairman and CEO.
Key Highlights
- Net loss for Q2 2026 was $1.25 million, compared to $1.04 million in Q2 2025.
- Net loss for H1 2026 was $2.06 million, a decrease from $7.15 million in H1 2025.
- Cash balance as of June 30, 2026, was $1.63 million, down from $1.83 million at year-end 2025.
- Company issued a going concern warning due to recurring losses and negative cash flows.
- Completed a private placement in April 2026, raising $0.7 million by issuing 17.5 million common shares.
- Entered into a license agreement with Cirna Diagnostics for liver disease diagnostic assets with a $70,000 upfront payment.
- Signed new employment agreements with Executive Chairman Vincent LoPriore ($280,000 base salary) and CEO Gary Stetz ($250,000 base salary).
- Post-period, completed a $3.1 million private placement in July 2026 by issuing 61.1 million common shares and warrants.
Price Impact
More from HEPA